Precision oncology and digitally enabled cancer care are transforming what it means to live with cancer. The number of people in Europe alive more than five years after a cancer diagnosis grew 41 percent between 2010 and 2020, to nearly 15 million. As science progresses, a growing number of advanced cancers could be managed as chronic diseases, like diabetes or hypertension. But many patients are only able to access innovative treatments as part of a clinical trial, and Europe’s share of global commercial trials has almost halved in a decade. Access to screening and advanced diagnostics also varies widely across the bloc.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.